Raising Capital in a Controversial Industry | Psychedelics & Mental Health | Building Investor Relationships | Showing Traction Before Regulatory Approval | Imposter Syndrome in LATAM Startups with Victoria Costa Paz, CEO @ EYWA | Ep 3

There is a lot of stigma around psychedelics.

Vicky is the CEO of EYWA, a biotech startup that produces molecules for mental health treatments. In this episode, we discussed the fundraising process for a startup working with psychedelics and the stigma surrounding the industry.

Topics in this episode

0:00 Intro  
1:07 Founding EYWA  
3:53 Advice for Startup Founders in LATAM  
8:51 What is Biosynthesis?  
12:34 What Molecules is EYWA Focusing On?  
13:35 How to Show Commercial Traction Before Regulatory Approval?  
15:03 The Psychedelics Ecosystem  
16:26 Scientific Data About Psychedelics  
23:51 What is EYWA's Business Model?  
25:49 How Does IP Shape an R&D Roadmap?  
27:56 Why Use AI and Bioinformatics?  
33:27 Regulatory Landscape for Psychedelics  
40:14 The Investors' Perception of Psychedelics  
44:17 EYWA's Most Recent Funding Round  
46:14 Building Relationships with Investors  
51:02 EYWA's Fundraising Plans  
51:37 Recording a TV Show with Tim and Adam Draper  
53:43 What's Next for EYWA  

Connect with Vicky on LinkedIn https://www.linkedin.com/in/victoria-costa-paz-a83499b2/
Follow EYWA on LinkedIn https://www.linkedin.com/company/eywabio/posts/?feedView=all 
Follow EYWA on Instagram https://www.instagram.com/eywa.bio/

Connect with JP Orlov on LinkedIn https://www.linkedin.com/in/jp-orlov/
Follow Science VC on LinkedIn https://www.linkedin.com/company/science-vc
Follow Science VC on Instagram https://www.instagram.com/science.vc

Subscribe to Science VC on YouTube https://www.youtube.com/@ScienceVC
Subscribe to our Newsletter https://substack.com/@jporlov

Learn how WeArePalta can help your deeptech company communicate its science and impact https://www.wearepalta.com/